asco-2026

Ozempic's 30 Percent Breast-Cancer Headline, and the Trial Evidence It Walked Past

A single-system observational study at ASCO 2026 attached a roughly 30% lower breast-cancer rate to GLP-1 use. The randomized record already on the table is quieter.